

The CNMC Concludes its Sanctioning Process Against Hermandad Farmacéutica del Mediterráneo

- The company acknowledges that it failed to comply with the commitments made during the acquisition of Farmacéutica Conquense and has paid the fine in advance.
- The CNMC approved the merger in October 2022, but Hermandad Farmacéutica was required to amend its articles of association, inform its members in writing about the commitments and submit documentation to the Commission.
- The company only amended its articles of association and therefore has been sanctioned.

Madrid, 07 April 2025. The Spanish National Markets and Competition Commission (CNMC) has fined Hermandad Farmacéutica del Mediterráneo, Soc. Coop. Ltda. (HEFAME) €86,000 for failing to fulfil the commitments it made after merging with Farmacéutica Conquense Sdad. Coop. CLM (COFARCU) in October 2022 ([C/1340/22](#)) ([SNC/DC/010/25](#)).

HEFAME committed to amending its articles of association, informing all its members in writing about the commitments undertaken and submitting documentation to the CNMC. The company has failed to notify its members and has not submitted the required information within the established deadline. This prevented the CNMC from verifying compliance ([see press release](#)).

The breach amounts to a very serious infringement of [Article 62.4.c\) of the Competition Defence Act](#) (LDC).

Admission of infringement and reduction of the fine

HEFAME has acknowledged its responsibility and has invoked Article 85.3 of Act 39/2015, which allows for a reduction of up to 40% in the amount of the fine. As a result, it ultimately paid €51,600.

The CNMC concluded the sanctioning process for breach of commitments after Hermandad acknowledged its responsibility and voluntarily paid the fine.

Related content:

- [SNC/DC/010/25](#)
- [C/1340/22](#): HEFAME/COFARCU
- [Press release](#) (12/02/2025): The CNMC initiates infringement proceedings against Hermandad Farmacéutica del Mediterráneo